Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
AKSO Biopharmaceutical
Los Angeles, California, United Statescn.linkedin.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
AKSO’s lead programs are in late preclinical development. AB001, a first-in-class soluble BCMA decoy receptor targeting APRIL and BAFF, has shown efficacy in mouse models of multiple myeloma and DLBCL with good safety in non-human primates. AB002 is a bi-functional fusion protein that neutralizes PD-L1/PD-L2 and activates NK cells via an IL‑15 agonist; it is being developed for solid tumors through a partnership for Asia-Pacific ex-Japan.
- Therapeutic areas
- OncologyRare DiseasesImmunologyHematologyNephrology
- Modalities
- Fusion proteinBispecific antibodyAntibody-drug conjugateRecombinant fusion proteinAntibody fusion proteins
- Industry
- Biotech
02
Partnerships
Huadong Medicine (for development/commercialization of AB002 in Asia-Pacific ex-Japan)Chime Biologics (CDMO partner for manufacturing support)
Beyond the preview
Go deeper on AKSO Biopharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AKSO Biopharmaceutical.